Finance

Lists
Why is CBLL up 6.46%?
Dive Deeper
CBLL:NASDAQ
CeriBell Inc
$27.68
+6.46%
(+1.68) 1D
$27.68
0.00% (0.00)
After hours
Closed: Oct 20, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBLL...
Open
$26.00
High
$27.91
Low
$26.00
Mkt. cap
1.06B
Avg. vol.
405.78K
Volume
592.44K
52-wk high
$27.93
52-wk low
$10.85
EPS
-$1.76
Shares outstanding
38.38M
No. of employees
327
Open
$26.00
High
$27.91
Low
$26.00
Mkt. cap
1.06B
Avg. vol.
405.78K
Volume
592.44K
52-wk high
$27.93
52-wk low
$10.85
EPS
-$1.76
Shares outstanding
38.38M
No. of employees
327
News stories
From web sources and news partners
About CeriBell Inc
CEO-
Employees327
Founded2014
HeadquartersSunnyvale, California, United States
SectorMedical device
Websiteceribell.com
Analyst ratings
Based on 6 analysts giving stock ratings to CBLL in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for CBLL in the last 3 months.
Highest
Current $27.68
$33.00 (+19.22%)
Average
$29.50 (+6.58%)
Lowest
$26.00 (-6.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Josh Jennings
TD Cowen
Buy
Maintained
$33.00
+19.2%
10/02/2026
Brandon Vazquez
William Blair
Buy
Reiterated
-
-
09/30/2026
Marie Thibault
BTIG
Buy
Reiterated
$30.00
+8.4%
09/21/2026
Unknown Analyst
Raymond James
Buy
Maintained
$29.00
+4.8%
09/03/2026
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
08/11/2026
William Plovanic
Canaccord Genuity
Buy
Maintained
$26.00
-6.1%
08/13/2026
Jeffrey Cohen
Ladenburg Thalmann & Co.
Buy
Reiterated
$32.00
+15.6%
05/12/2026
Last report
Aug 10, 2026
Fiscal period
Q2 2026
-$0.40 / -$0.46
+11.94%beat
Revenue / Est. (USD)
28.10M / 27.28M
+2.99%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
22.59M
24.78M
26.49M
28.10M
Cost of goods sold
2.65M
3.14M
3.37M
2.16M
Cost of revenue
2.65M
3.14M
3.37M
2.16M
Research and development expenses
4.98M
5.06M
6.16M
6.75M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.61M
31.18M
32.11M
39.17M
Operating expense
34.59M
36.24M
38.27M
45.92M
Total operating expenses
37.24M
39.38M
41.64M
48.08M
Operating income
-14.65M
-14.60M
-15.15M
-19.98M
Other non operating income
1.66M
1.53M
1.44M
1.15M
EBT including unusual items
-13.46M
-13.53M
-19.74M
-19.27M
EBT excluding unusual items
-13.46M
-13.53M
-14.14M
-19.27M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-13.46M
-13.53M
-19.74M
-19.27M
Net profit margin
-59.61%
-54.58%
-74.50%
-68.58%
Earnings per share
-0.37
-0.36
-0.38
-0.40
Interest and investment income
-
-
-
-
Interest expense
-480.00K
-462.00K
-434.00K
-438.00K
Net interest expenses
-480.00K
-462.00K
-434.00K
-438.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-14.26M
-14.30M
-14.91M
-19.74M
Gain or loss from assets sale
29.00K
25.00K
34.00K
28.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps